Accueil Ernstrade Bourse Actualite Stock

plus500
Frankfurt

The Group's principal activity is to conduct molecular diagnosis for the early detection and treatment of cancer and other complex diseases. The Group's products are based on DNA methylation, which are aimed at making early detection and treatment easier, more accurate and more convenient for the patient. The Group compares patient's cells against healthy and sick reference samples, which enables an exact diagnosis of disease at a very early stage and provides physicians with essential information to help guide the appropriate therapy. The group operates in Europe and North America.

http://www.epigenomics.com


 

Copyright   2009 Ernstrade.com